tening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at
www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors. Important factors that may cause such a difference for Masimo in connection with our litigation with Philips include, but are not limited to: our ability to prevail in the lawsuit against Philips,
'/>"/>
Page: 1 2 3 4 Related medicine news :1.
Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care2.
Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference3.
Masimo Launches First Non-adhesive Pulse Oximetry Sensor Designed For Extremely Low Birth Weight Babies4.
Masimo Reports Second Quarter 2008 Financial Results5.
Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology6.
First Nursing Facility Installation of Masimo Patient SafetyNet(TM) Goes Live With Remarkable Results7.
Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors8.
Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin9.
Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry10.
Masimo to Report First Quarter 2008 Financial Results on April 29, 200811.
Masimo to Report Fourth Quarter and Fiscal Year 2007 Financial Results on February 26, 2008